⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplemental Figure S8 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

Victor J. Collins Katelyn R. Ludwig Ariana E. Nelson Soumya Sundara Rajan Choh Yeung Ksenia Vulikh Kristine A. Isanogle Arnulfo Mendoza Simone Difilippantonio Baktiar Karim Natasha J. Caplen Christine M. Heske

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Defining parameters for the evaluation of effects of DNA-PK inhibitors plus TOP2 poisons in preclinical models of EWS

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Collins et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574b09 https://doi.org/10.1158/1535-7163.26423713.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure S8 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
2Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
3Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
4Supplemental Figure S5 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
5Supplemental Figure S5 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
6Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
7Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024
8Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma2024